Background: Many youth with type 1 diabetes do not achieve glycemic targets motivating the development of new therapeutic options for this population. We tested an automated insulin delivery system (AID) that uses a multi-model model predictive controller in children with T1D.
Methods: We conducted a 40-hour free-living clinical trial to assess our automated insulin delivery algorithm in children aged 7-13 years old with T1D (mean age 10.5±2.0 years, HbA1c 7.9±0.7%, duration of T1D 5.2±2.8 years) . Participants underwent a 7-day run-in period on sensor-augmented pump therapy followed by two 40-hour intervention periods composed of four hours of open-loop and 36 hours of AID use. Controller settings were identical in both intervention periods. Mean time-in-ranges were compared by paired T-test.
Results: Time in target (3.9-10mmol/L) and time in hyperglycemia (>10mmol/L) improved during intervention periods vs. run-in (52.2% vs. 65.6%; p<0.and 45.1% vs. 30.8%; p=0.respectively) while time in hypoglycemia (<3.9mmol/L) during intervention periods was unchanged from the run-in (1.8 vs. 2.0%, p=0.96) .
Conclusion: Early results suggest our advanced model predictive controller improves glucose control in a 7-13-year-old population with T1D. Larger and longer trials are warranted.
E.Palisaitis: Other Relationship; Eli Lilly and Company. R.Jones: Employee; Eli Lilly and Company, Stock/Shareholder; Eli Lilly and Company. M.Katz: Employee; Eli Lilly and Company, Stock/Shareholder; Eli Lilly and Company. H.Wolpert: Employee; Lilly Diabetes. A.El fathi: Other Relationship; Eli Lilly and Company. A.Haidar: Consultant; Eli Lilly and Company, Research Support; ADOCIA, Dexcom, Inc., Eli Lilly and Company, Tandem Diabetes Care, Inc. J.E.Von oettingen: None. L.Legault: Advisory Panel; Abbott Diabetes, Insulet Corporation, Novo Nordisk A/S, Other Relationship; Eli Lilly and Company, Research Support; AstraZeneca, Merck & Co., Inc.